Can UCB Make Its Mark In Myasthenia Gravis?

Playing Catch-Up With Alexion And Argenx

 
• By Kevin Grogan
  
Market share
UCB hopes to get a decent slice of the myasthenia gravis market • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip